ABBV vs ZNTL
ABBV: A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity. ZNTL: Zentalis Pharmaceuticals is developing azenosertib, a potentially first-in-class, oral, small-molecule WEE1 inhibitor as a targeted treatment for ovarian and other solid tumors.
Side-by-side fundamentals
| Metric | ABBV | ZNTL | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $289.08 | $2.39 | |
| Market cap | $510.8B | $171M | |
| P/E as of 2026-10-20 | 81.66 | n/a | |
| Net margin FY2025, SEC XBRL | +6.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +24.6% | n/a | |
| ROE FY2025, SEC XBRL | n/a | -63.4% | |
| ROA FY2025, SEC XBRL | +3.2% | -47.4% | ABBV higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.8% | n/a | |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 9 | 0 | ABBV higher |
| Beta as of 2026-09-03 | 0.26 | 1.66 | |
| 1-year return as of 2026-10-20 close | +24.6% | +54.2% | ZNTL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.